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tivity of 82% and speciﬁcity of 75%. Taken together, these data
demonstrate that molecular proﬁles can be generated which are
highly predictive of different levels of radiation exposure in
mice and humans. We suggest that this approach, with addi-
tional reﬁnement, could provide a method to assess the effects of
various environmental inputs into biological phenotypes as well
as providing a more practical application of a rapid molecular
screening test for the diagnosis of radiation exposure.
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HIGH PREVALENCE OF BONE LOSS IN LONG TERM SURVIVORS FOL-
LOWING ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Donohue, T.B.1, Savani, B.N.1, Shenoy, A.1, Kozanas, E.1,
Singh, A.K.2, Childs, R.W.1, Barrett, A.J.1 1Stem Cell Transplant
Secotion, Hematology Branch; NHLBI, National Institutes of Health,
Bethesda, MD; 2Radiation Biology Section; NCI, National Institutes of
Health, Bethesda, MD.
Bone loss (osteopenia/osteoporosis) is a complication following
allogeneic stem cell transplantation (SCT). After written consent
patients surviving more than three years post-transplant were en-
rolled in a long-term follow-up study (started in April 2005) which
included an annual DEXA scan. Sixty-three patients (median age
35 years) received a fractionated total body irradiation (TBI) (12-
13.6 Gy) based myeloablative SCT (MST) and 9 patients (median
age 37 years) received a non-TBI non-myeloablative SCT (NST).
Age of patients at transplantation ranged from 6 to 66 (median 35
years). The indication for SCT was CML (43), MDS (11), AML
(11), ALL (3), CLL (2), SAA (1), and mastocytosis (1). Seventy-two
(41M,31F) patients underwent DEXA scanning. Seventy (97%)
patients are alive at a median follow-up of 73 months (range
32-155); Acute graft versus host disease (GVHD) occurred in 41
(57%) patients and chronic GVHD in 61 (85%). Twelve (17%)
patients at a median follow up 37 (range 32-106 months) were
receiving immunosuppressive therapy (IST) for chronic GVHD at
the time of analysis. All patients were advised to take vitamin D and
calcium supplements after transplantation and all but one female
were taking hormone replacement therapy at the time of DEXA
scanning. Fifty-three (74%) of patients had bone loss in at least one
site measured - 30 (42%) with osteopenia and 23 (32%) with
osteoporosis. There was a preponderance of osteopenia and osteo-
porosis in typical sites such as AP spine (22% and 18%); femoral
neck (46% and 6%); and femur (Ward’s area) (38% and 8%); total
hip (36% and 1%); but also in the forearm (24% and 13%) likely
related to steriod therapy. Mean T score of adult patients was
-1.8  0.16 (male -1.9  0.2; female -1.6  0.3); while mean Z
score of 5 children (age 18) was -1.6  0.45. Factors associated
with signiﬁcant increase risk of bone loss were: age more than
median (p0.03) and prolonged IST (12/12 vs. 41/60; p0.017 for
bone loss and 8/12 vs.15/60; p0.008 for osteoporosis). When
patient age was analyzed by quartiles, the oldest quartile (range
44-66) was profoundly impacted for osteoporosis (mean T score
-2.3 0.25; p0.016). There was no signiﬁcant difference in bone
loss with regard to sex, stem cell source, disease, TBI dose, acute
GVHD, or chronic GVHD. In summary, we found a very high
prevalence of bone loss in long term survivors of SCT. Bone loss
is associated with older age at transplant and continuing treatment
of chronic GVHD.
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15 YEARS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BETA
THALASSEMIA MAJOR IN TEHRAN
Gavamzadeh, A.1, Ali Mogaddam, K.1, Nedaeifard, L.1, Jahani, M.1,
Mousavi, A.1, Iravani, M.1, Bahar, B.1, Khodabandelu 1 Hematology-
Oncology and BMT Research Center, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran.
Objective: Beta Thalassemia Major is the most common type of
haemoglobinopathies in Iranian patients. We reported results of 15
years HSCT in our centre.
Method: 277 Beta Thalassemia Major Patients, 158 male and
119 female with median age of 6 years old (range 2.5-26 y), have
been transplanted from 1991 till march 2006 in our centre.
92 patients were class one, 103 class two and 74 class three
according to Dr.Lucarelli classiﬁcation. They have received
allogeneic transplantation from 266 HLA full matched siblings
and 11 other relatives. Source of hematopoietic cells were 136
bone marrow, 133 peripheral blood and 8 cord blood. The most
common conditioning regimen was Bu/Cy without TBI and
their GVHD prophylaxis regimen was Cyclosporine  Metho-
traxate.
Results: 229 (82.7%) patients are alive and 48 (17.3) dead.
Acute GVHD occurred in 61.3% patients and chronic GVHD
in 4.7% patients and both type in 34% patients. Graft rejection
occurred in 60 (21.7%) patients. The most common cause of
death was acute and chronic GVHD. Venooclussive disease
occurred in 17 patients. Five years overall (OS) and thalassemia
free survival (DFS) were 79% and 65% respectively. OS and
DFS of transplanted patients from HLA- identical siblings were
better than transplanted patients from other relatives’ donors.
There were not any signiﬁcant differences in OS of patients in
different classes of disease or sources of HCT. But DFS of class
one was better than three. OS and DFS were better in patients
with acute GVHD and older donors.
Conclusion: HCT based on our experience and other docu-
mented studies is acceptable treatment for Beta Thalassemia
Major with better result in younger patients.
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THE INCIDENCE OF SECONDARY MALIGNANCY AFTER STEM CELL
TRANSPLANTATION, THE IMPORTANCE OF TOTAL BODY IRRADIATION
Ghavamzadeh, A.1, Samiee, S.1, Mahdavi, N.1, Bakhti, O.1,
Jahani, M.1, Alimoghaddam, K.1, Iravani, M.1, Bahar, B.1,
Khodabandeh, A.1, Mousavi, A.1 1Hematology-Oncology and BMT Re-
search Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Purpose: In this study we studied the records of 1586 recipi-
ents of autologous or allogeneic-related and -unrelated and
syngeneic bone marrow transplants (BMTs) between 1991 till
2006 to determine the incidence of secondary malignancies and
importance of Total Body Irradiation as a risk factor.
PATIENTS AND METHODS : 829 patients were under-
gone transplantation for acute lymphocytic leukemia (ALL; n 
212), acute myelogenous leukemia (AML; n  429), and chronic
myelogenous leukemia (CML; n  188) while 162 patients for
Lymphoma, 98 for aplastic anemia (AA), 284 for Thalassemia
and 213 patients for a variety of other hematologic and nonhe-
matologic disorders, malignant and nonmalignant. Condition-
ing regimens included high-dose chemotherapy without total-
body irradiation (TBI). Patients who were missed to follow-up
were excluded from the study on the time of missed to follow up.
RESULTS: 9 patients developed 9 secondary cancers for a one
year risk of 1.2%, ﬁve year risk of 2.4% and ten year risk of
2.9%. Of all the 9 patients 5 (55.5) were male, and 4(44.4%)
were female. The median age was 21 years old; with minimum
and maximum of 13 and 28 y/o respectively. 6(66.6%) patients
received allogeneic stem cell transplantation and 3(33.3%) re-
ceived autologous transplantation. 5 patients (55.5%) had pe-
ripheral blood as graft type. The conditioning regimen for
4(44.4%) of patients was Busulphan and Cyclophosphamide, 1
patient had Busulphane, Cyclophosphamide and Etoposide, 3 of
them had Cyclophosphamide, Etoposide and Ara-C. The other
1 patient had ATG, Cyclophosphamaide and Fludarabine as
conditioning regimen. The median follow-up duration for all
our patients was 376 days, (1-4749) which was 300 days for these
9 patients who developed new malignancy. (45-1125) .Overall
Mortality Rate is 66.6% and the cause of death in 33.3% of
patients is new malignancy.
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1 MDS Lymphoma 954
2 AML-M4 Lymphoma 282
3 AML-M2 Lymphoma 594
4
NHL Small non clear cell,
Burkit Gastric cancer 451
5
NHL Large cell anaplastic
Lymphoma, Ki 1  CML 31
6 Fanconi Anemia Lymphoma 301
7 CML Ph1 , BCR ABL  Lymphoma 165
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A NEW CONDITIONING REGIMEN IN THALASSEMIA MAJOR CLASS 3 AN
EXPERIENCE OF IRAN FROM 2004 TILL 2006
Iravani, M.1, Alimogaddam, K.1, Khatami, F.1, Jalili, M.1,
Tagipur, R.1, Bab hadiashar, N.1, Gaffari, F.1, Mousavi, A.1,
Jahani, M.1, Bahar, B.1, Khodabandelu, Gavamzadeh, A.1 1Hematol-
ogy-Oncology and BMT Research Center, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran.
Objective: Resent studies have showed the efﬁcacy of Fludarabin
(Flu) and Busulfan (BU) as a conditioning regimen in senile and
high risk leukemia patients. This regimen has good safety proﬁle
and transplant related complication such as cardiopulmonary and
liver dysfunction is venial. We used Flu (40 mg/m2/4 days) and Bu
(4mg/kg/4days) for patients who are at risk of rejection, Graft
Versus Host Disease (GVHD) and cardiopulmonary complications
(Thalassemia class 3) as myeloablative conditioning regimen for
HLA match sibling allogeneic stem cell transplantation.
Methods: Since August 2004 till September 2006, six patients
with Thalassemia class III received blood and marrow transplan-
tation from their HLA-identical siblings. One patient received
bone marrow and ﬁve patients received peripheral blood stem cell
transplantation. Conditioning regimen was Flu 40 mg/m2 (from
day–6 to -2) and Busulfan 4 mg/kg/day (from day –5 to -2).
GVHD prophylaxis regimen was cyclosporine.A 3mg/kg /day/IV
(days –3, 7), then 12.5 mg/kg/day/PO.
Results:Median age at time of transplantation was 19 years (Age
range: 11-26.5), Male/Female:5/1. Median Mononucleated cells
were 5.02/kg  108 and median CD34 was 2%. Median time of
absolute neutrophil count 0.5109 /L was20 and Median time
of platelet recovery 20109 /L was 31. Two patients (33.3%)
developed acute GVHD (grade I: 1, grade III: 1) and three patients
(50%) developed chronic GVHD (limited). Three patients (50%)
had Mocusitis and two ones (33.3%) had Nutropenic fever and
three patients had elevated liver enzymes. Till now all patients are
alive and we have just one relapse.
Conclusion: According to this study Flu/BU as a conditioning
regimen is safe and effective in Thalassemia class 3 patients.
Key Words: Blood and marrow transplantation, Thalassemia
class 3.
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LATE EFFECTS IN SURVIVORS OF HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA TREATED WITH AUTOLOGOUS HEMATOPOIETIC CELL
TRANSPLANTATION: A REPORT FROM THE BONE MARROW TRANS-
PLANT SURVIVOR STUDY
Majhail, N.S.1, Ness, K.K.1, Burns, L.J.1, Carter, A.2, Francisco, L.2,
Sun, C.-L.2, Forman, S.J.2, Bhatia, S.2, Baker, K.S.1 1University of Min-
nesota, Minneapolis, MN; 2City of Hope Cancer Center, Duarte, CA.
We conducted a retrospective cohort study to evaluate late effects of
autologous hematopoietic cell transplantation (HCT) in Hodgkin’s
lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) survivors.
Eligible subjects received HCT at either City of Hope or University
of Minnesota between 1974 and 1998, were 18 years or older at the
time of interview and had survived for 2 years or more after HCT. A
random sample of siblings of study participants was recruited for
comparison. All participants (n92 HL, n184 NHL, n319 sib-
lings) completed a 238 item questionnaire. Median age at HCT was
39 years (range, 13-69) and median followup was 6 years (range, 2-17)
since HCT. Median age at completion of survey was 46 years (range,
21-73) for HCT survivors and 44 years (range, 19-79) for siblings.
Patient characteristics were similar between HL and NHL groups
except a higher proportion of NHL survivors received total body
irradiation (TBI) as part of their conditioning (83% vs 40%). Com-
pared to siblings (after adjusting for age at interview and sex), HCT
survivors reported a signiﬁcantly higher frequency of cataracts (14%
vs 4%), dry mouth (14% vs 1%), hypothyroidism (19% vs 7%), bone
impairments (osteoporosis and avascular necrosis) (7% vs 3%), con-
gestive heart failure (4% vs 0.3%), exercise induced shortness of
breath (10% vs 3%), neurosensory impairments (33% vs 20%), sec-
ond cancers (8% vs 2%), and inability to attend work or school due to
health impairments (16% vs 2%). 84% subjects rated their overall
health as good, very good or excellent compared to 95% siblings
(p0.001). Multivariate models adjusted for age at HCT and time
since HCT simultaneously considered the effects of sex, diagnosis
(HL vs. NHL) and conditioning regimen (TBI vs. no TBI). Com-
pared to those receiving no TBI, patients treated with TBI based
conditioning had higher risks of cataracts (odds ratio (OR) 4.9, 95%
CI: 1.5-15.5) and dry mouth (OR 3.4, 95%CI: 1.1-10.4). Females had
a greater likelihood of reporting hypothyroidism (OR 2.5, 95% CI:
1.3-4.7), osteoporosis (OR 8.7, 95% CI: 1.8-41.7), congestive heart
failure (OR 4.3, 95% CI: 1.1-17.2) and abnormal balance, tremor or
weakness (OR 2.4, 95% CI: 1.0-5.5). In conclusion, HL and NHL
survivors of autologous HCT have a high prevalence of long-term
health-related complications and require continued monitoring for
late effects with timely introduction of appropriate interventions.
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5 CASES OF PERMANENT ALOPECIA AFTER VARIOUS CONDITIONING
REGMIENS COMMONLY USED IN BONE MARROW TRANSPLANTATION
Machado, M.1, Moreb, J.1, Khan, S.A.1 1University of Florida College
of Medicine, Department of Medicine, Division of Hematology/Oncology,
Gainesville, FL.
Alopecia, a common side effect of chemotherapy, is usually tempo-
rary and reversible within few months. Irreversible alopecia has been
reported (36 patients in 5 reports) after high dose chemotherapy
(HDC) and hematopoetic stem cell transplantation (HSCT) espe-
cially related to busulfan and cyclophosphamide containing condition-
ing regimens; however the overall incidence is not known. We de-
scribe 5 patients who experienced permanent alopecia after HSCT
including 2males and 3 females.Median age at transplant was 43 years
(Range 37-55), 3 were Caucasians and 2 African American. Diagnosis
included: Ewing sarcoma (1), multiple myeloma (2), CML (1) and
AML (1). Three patients received autologous peripheral blood stem
cell transplant (ASCT) one of them had tandem transplant, one
underwent matched sibling allogeneic transplant and one received
umbilical cord blood transplant. Total of 760 transplants were per-
formed in our institution during that period (1997-2004). Condition-
ing regimens included BuCyVP16 (busulfan, cyclophosphamide and
etoposide) in 2 patients, one of these patients received 2nd ASCT with
CyTBI, BuCy (2 patients) and CyVP16TBI (1 patient). Patients were
followed in our outpatient clinic with median follow up from last
transplant of 40 months (Range 19 to 58 months). Two of the females
and one of the male patients had complete alopecia, while the other
male and female had alopecia areata. In all ﬁve cases however, there
was no re-growth of hair. In one patient who received BuCy, there
was evidence of chronic graft vs host disease which had completely
resolved after 6 mos treatment. The current disease status is complete
remission (3), and partial remission in two patients with multiple
myeloma. All patients received Cy, 4 received Bu, three had VP-16
and 2 patients had TBI containing combinations. This data shows that
permanent alopecia is a signiﬁcant long-term side effect of HSCT and
can be seen across the spectrum of diseases and transplant types. Our
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